DTIL
What one share of Precision Biosciences holds
Biological Products, (No Diagnostic Substances)
We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure.
Precision Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.21 |
|---|---|
| Profit | −$2.59 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.55 |
| Cash and investments | $3.31 |
| Book value | $1.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $20.70 | −$87.55 | $27.15 | −$125.51 | — | $75.36 |
| 2019 | $764.45 | −$66.35 | $17.62 | −$68.36 | — | $81.11 |
| 2020 | $14.00 | −$62.85 | $2.90 | −$53.28 | — | $25.29 |
| 2021 | $59.06 | −$15.64 | $2.58 | −$8.13 | — | $44.91 |
| 2022 | $8.57 | −$38.10 | $1.13 | −$16.75 | — | $16.34 |
| 2023 | $12.68 | −$15.96 | $0.51 | −$22.41 | — | $4.53 |
| 2024 | $9.98 | $1.04 | $0.04 | −$8.53 | — | $6.87 |
| 2025 | $2.67 | −$3.56 | $0.01 | −$5.14 | — | $3.83 |